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Objective: We examined the effects of stress, depressive symptoms, and social support on the progression of HIV
infection. Methods: Eighty-two HIV-infected gay men without symptoms or AIDS at baseline were followed up
every 6 months for up to 5.5 years. Men were recruited from rural and urban areas in North Carolina as part of the
Coping in Health and Illness Project. Disease progression was defined using criteria for AIDS (CD41 lymphocyte
count of ,200/ml and/or an AIDS-indicator condition). Results: We used Cox regression models with time-
dependent covariates, adjusting for age, education, race, baseline CD41 count, tobacco use, and number of
antiretroviral medications. Faster progression to AIDS was associated with more cumulative stressful life events
(p 5 .002), more cumulative depressive symptoms (p 5 .008), and less cumulative social support (p 5 .0002). When
all three variables were analyzed together, stress and social support remained significant in the model. At 5.5 years,
the probability of getting AIDS was about two to three times as high among those above the median on stress or
below the median on social support compared with those below the median on stress or above the median on
support, respectively. Conclusions: These data are among the first to demonstrate that more stress and less social
support may accelerate the course of HIV disease progression. Additional study will be necessary to elucidate the
mechanisms that underlie these relationships and to determine whether interventions that address stress and social
support can alter the course of HIV infection. Key words: HIV, AIDS, stress, social support, depression.
HIV 5 human immunodeficiency virus; HDRS 5 Ham-
ilton Depression Rating Scale; CDC 5 Centers for Dis-
ease Control and Prevention.
INTRODUCTION
There is growing evidence that psychosocial factors,
such as stress and depression, may have a harmful
impact on the outcome of a variety of diseases (1–6).
For example, among cancer patients, severe life stress
has been associated with a greater probability of re-
lapse (5), and psychosocial interventions to improve
coping with stress have resulted in longer survival
(3, 4). Although there is evidence that stress and de-
pression may impair cellular immunity (7–12), the
clinical relevance of these alterations has not been
established in HIV.
Given the multifactorial nature of HIV disease, and
the wide variability in the progression of HIV infec-
tion, recent studies have examined the impact of psy-
chological variables on the course of this disease (13–
21). We found stress-associated reductions in killer
lymphocytes in HIV-infected men at baseline (16) and
recently reported that severe stress and depressive
symptoms were related to declines in several lympho-
cyte subsets over a 2-year period (20). Furthermore, we
found that severe stress was associated with a greater
risk of early HIV disease change in men studied for up
to 3.5 years (21). For the investigation described in this
report, we followed the same cohort for up to 5.5 years
to examine the effects of stress, depressive symptoms,
and social support on progression to AIDS.
Findings on the importance of stress and depression
in predicting decline in immune status and disease
course have been inconsistent. In one meta-analysis,
depressive symptoms, but not stressors, were shown to
be longitudinally related to self-reported symptoms of
HIV infection (17). Furthermore, neither stress nor de-
pressive symptoms were related to changes in CD41
lymphocyte numbers in peripheral blood or other
commonly accepted markers of HIV disease progres-
sion. Stress, however, was associated with declines in
natural killer cell cytotoxicity and numbers of natural
killer cells, a finding consistent with those of our re-
cent studies (16, 20). The mixed findings in the meta-
analysis may be explained by the cited studies having
short follow-up periods and measuring depressive
symptoms only at baseline rather than making re-
peated assessments more proximal to disease change.
More recent studies, conducted over longer time
intervals, have found significant relationships be-
From the Departments of Psychiatry (J.L., E.D.J., R.N.G., S.G.S.,
D.O.P.), Medicine (J.L.), and Pathology and Laboratory Medicine
(J.D.F.), University of North Carolina School of Medicine, Chapel
Hill, North Carolina; Department of Biostatistics, University of
North Carolina (J.C.), Chapel Hill, North Carolina; Departments of
Psychiatry, Neuroscience, and Pharmacology, University of Florida
College of Medicine (J.M.P.), Gainesville, Florida; and Departments
of Psychiatry, Medicine, and Neuroscience, University of Pennsyl-
vania School of Medicine (D.L.E.), Philadelphia, Pennsylvania.
Address reprint requests to: Jane Leserman, PhD, Research Asso-
ciate Professor, Department of Psychiatry, CB 7160, University of
North Carolina School of Medicine, Chapel Hill, NC 27599-7160.
Email: JLeserman@css.unc.edu
Received for publication September 23, 1998; revision received
January 28, 1999.
397Psychosomatic Medicine 61:397–406 (1999)
0033-3174/99/6103-0397
Copyright © 1999 by the American Psychosomatic Society
tween depressive symptoms and HIV disease progres-
sion. In the San Francisco Men’s Health Study, a
9-year longitudinal study of seropositive men, re-
searchers found that higher levels of depression at
entry were associated with faster progression to AIDS
(19). Median time to first AIDS diagnosis was 6.2 years
for those who were depressed at baseline, compared
with 7.6 years for those who were not depressed.
These findings at 9 years are at odds with earlier data
at 5 years from the same cohort. The earlier data
showed no relationship between baseline depression
and AIDS diagnosis, although an association between
depression and decline in CD41 lymphocytes was
found at this time point (14). In another recent analysis
of the same cohort, researchers found that those who
had elevated depression symptoms at every visit had a
1.7 times greater risk of mortality compared with those
who never had an elevated depression score (18).
An initial analysis from the Multicenter AIDS Co-
hort Study found no relationship between depression
at study entry and progression of HIV infection, de-
fined as time to AIDS, death, or decline in CD41 lym-
phocytes (15). In later analyses of these data, research-
ers found that self-reported depressive symptoms
seemed to rise 1.5 years before AIDS diagnosis (22).
The researchers interpret these findings as an indica-
tion that depression may increase toward the later
stages of HIV infection and thus be a manifestation of
the disease process. A subsequent survival analysis of
these data, however, using level of depressive symp-
toms during the 6 months before AIDS diagnosis,
showed no relationship between depression and time
to death (23).
Fewer studies have examined the impact of stress
and social support on disease progression. In previous
analyses of our cohort, we showed that the risk of early
HIV disease progression was doubled with every se-
vere stressor per 6-month study interval (21). Stress
was measured by interview using ratings based on the
context or specific circumstances surrounding the
events or difficulties. In addition, we found that stress
and depressive symptoms, especially in combination,
were associated with decreases in natural killer and
CD81 cytotoxic T lymphocyte numbers, but not de-
clines in number of CD41 T-helper cells, from entry to
2-year follow-up (20). Using a similar interview-based
stress rating to that used in the present study, the San
Diego Neurobehavioral HIV Center found that those
who reported no severe life stress and few depressive
symptoms had less decline in the percentage of CD41
lymphocytes after 6 months compared with those with
higher scores on these psychological risk factors (24).
Similarly, Ironson et al. (25) found that men with
greater distress at the time of HIV serostatus notifica-
tion had a greater chance of developing HIV-related
clinical symptoms at 2-year follow-up. Another study
showed that the stress of bereavement before study
entry was associated with more rapid decline in CD41
count over 3 to 4 years (26). It is noteworthy that
studies using short follow-up periods and/or question-
naire methods to assess life stress have not shown an
association of stress with reduction in CD41 lympho-
cyte counts over time (27–29).
Studies that have examined the effects of social
support on HIV disease progression are lacking. In a
small study of hemophiliac patients, those with less
social support had faster deterioration in CD41 lym-
phocyte counts over a 5-year period (30). Another
study showed that HIV-infected subjects were more
likely to become symptomatic after 6 months if they
had less social support, but only among those with low
initial CD41 lymphocyte counts (31).
In this article, we report findings in a cohort of gay
men studied every 6 months for up to 5.5 years. We
hypothesized that higher scores on measures of de-
pression, more stressful life events, and less social
support would put men at greater risk for faster HIV
disease progression to AIDS. The study design in-
cluded several notable features: (1) stressful life events
were based on contextual ratings from a semistruc-
tured interview, (2) time-dependent covariates in sur-
vival analysis were used to assess psychosocial effects
on disease progression, (3) subjects were followed pro-
spectively for up to 5.5 years, and (4) none of our
subjects were taking protease inhibitors before disease
change—(protease inhibitors are the most effective
medical treatment for preventing HIV viral replica-
tion).
METHODS
Study Group
Data were collected in North Carolina as part of an ongoing
longitudinal study, the Coping in Health and Illness Project. The
study was approved by the University of North Carolina School of
Medicine Committee for the Protection of the Rights of Human
Subjects, and all subjects provided written informed consent. The
study group included 82 HIV-infected gay men recruited from rural
and urban areas of North Carolina from 1990 to 1992. All subjects
were clinically asymptomatic with CD41 lymphocyte counts above
200/ml at study entry. Men were assessed at 6-month intervals for up
to 5.5 years (12 visits). All subjects had at least two visits (mean
number of visits 5 8.52, SD 5 2.99).
All volunteers were screened to exclude from initial participa-
tion those with (1) less than 10 years of education; (2) age of less than
18 or more than 50 years; (3) previous intravenous drug use; (4)
significant medical illness (eg, heart, lung, or kidney disease); (5)
preexisting neurological disorder or trauma (eg, head injury, stroke,
or seizures); (6) past treatment for alcoholism or current heavy
alcohol use (.60 drinks per month); (7) present or past heavy rec-
reational drug use; (8) use of zidovudine or other antiretroviral
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medications; and (9) HIV-related symptoms, that is, those meeting
the 1987 CDC criteria for AIDS or AIDS-related complex (32) (eg,
night sweats; herpes zoster; oral candidiasis; hairy leukoplakia;
shingles; unexplained temperature, diarrhea, weight loss, or fatigue
in the presence of other symptoms).
Procedure
Subjects were evaluated every 6 months at the General Clinical
Research Center at the University of North Carolina, Chapel Hill.
Subjects underwent systematic medical, neurological, neuropsycho-
logical, and psychiatric assessments performed by specialists in
these areas. All subjects were asked to abstain from over-the-counter
medications known to affect immune response, recreational drugs,
and alcohol consumption for at least 2 weeks before each study visit;
we did not perform a toxicology screen to confirm compliance.
At each visit, subjects took nothing by mouth starting at midnight
before blood was drawn the next morning. Subjects were recumbent,
and an intravenous line was started at 8:00 AM in an antecubital
vein, which was kept patent with a slow normal saline drip. To
control for circadian effects, and the possibility of acute stress reac-
tion from insertion of the intravenous line, blood was drawn after 70
minutes of rest after line placement (33).
Measurement
All psychological, psychosocial, and medical variables were
measured every 6 months, except social support, which was as-
sessed yearly. To take advantage of the data gathered at each time
point, we used survival analysis with time-dependent covariates, as
explained in the statistical section of this article. For more details on
the measures, see our previous articles (16, 20).
Depression
To determine whether subjects had a major depression during
each 6-month interval, all men underwent a structured psychiatric
interview (modified Structured Clinical Interview for DSM-III-R Dis-
orders) (34); diagnoses were assigned at consensus diagnostic con-
ferences (35). Severity of depressive symptoms was measured with
the interviewer-based HDRS (36). We eliminated six of the 17 med-
ical symptom items (eg, somatic symptoms, weight loss, and retar-
dation) that overlapped with symptoms of HIV disease to help avoid
confounding the measure with disease progression. In a previous
article, we reported a high correlation between the original scale
(HDRS-17) and the 11-item version (HDRS-11) (20). Higher scores on
the HDRS-11 indicated more depressive symptoms during the pre-
vious week.
Stressful Life Events
To obtain information about stressful life events and difficulties,
we modified the semistructured interview, the Psychiatric Epidemi-
ology Research Interview (37). Subjects indicated which of the 111
stresses they had experienced during the preceding 6 months. Inter-
viewers questioned subjects in detail about the context of endorsed
events (discrete incidents, eg, losing a job, a death, or relationship
breakup) and difficulties (chronic stresses occurring over a 1-month
period or more, eg, financial difficulties, caretaking, or ongoing
conflict at work). Stresses were objectively rated using a manual of
norms and vignettes, a methodology similar to that developed by
Brown and Harris (38) and modified by Patterson et al. (24) and
Grant et al. (39). Norms for each stress were based on the degree of
threat that most people would experience given the particular cir-
cumstances (eg, financial impact, degree of control, life threat, and
personal involvement). The objective threat rating was made inde-
pendent of the subject’s rating and his way of coping with the stress,
to reduce the possibility that worsening disease led to poorer coping
and higher stress scores.
One of two trained raters (previously shown to have high inter-
rater reliability) (16) used the manual to rate, from 0 (no threat) to 4
(severe threat), the long-term impact (1 week after the event) of each
stressful event and the threat associated with each difficulty. All
ratings for each stressful event and difficulty were summed at each
visit, except that we removed those stresses that we knew were
likely to be caused by disease progression (eg, drop in CD41 count or
retirement due to HIV worsening).
Social Support
To assess the degree of satisfaction with social support, we ad-
ministered the Sarason Brief Social Support Questionnaire (40) on a
yearly basis (Cronbach’s a at baseline 5 0.89) (41). The scale can
range from 1 (very dissatisfied with the support received) to 6 (very
satisfied). Support scores from the previous yearly interval were
used to estimate scores at each 6-month visit. The correlation be-
tween visits 1 year apart ranged from 0.40 to 0.68. The Sarason Brief
Social Support Questionnaire also allows for quantification of num-
ber of support persons.
Disease Status
All of the men knew their HIV status at baseline, which was
based on enzyme-linked immunosorbent assay screening with West-
ern blot analysis for confirmation of the presence of anti-HIV anti-
bodies. We defined disease progression as the first time point when
a subject met the CDC AIDS surveillance case definition (42), that is,
reduction in CD41 lymphocytes to below 200/ml and/or presence of
an AIDS-indicator condition (clinical stage C). A comprehensive
physical examination was performed every 6 months by a clinician
trained to assess HIV disease stages. Peripheral blood CD41 lympho-
cyte counts were performed by flow cytometry using commercially
prepared monoclonal antibodies (Becton Dickinson, Mountain
View, CA). Absolute CD41 count was derived from CD41 cell per-
centages 3 total lymphocytes 3 100.
Control Variables
We assessed the number of antiretroviral medications used (eg,
zidovudine, dideoxyinosine, and dideoxycytidine) every 6 months.
No subjects were on antiretroviral medication at study entry; how-
ever, the number of antiretroviral medications used ranged from
zero to three during the study. Age, years of education, race (non-
white or white), and use of tobacco (presence or absence) were
obtained at baseline by questionnaire.
Statistical Methods
We computed descriptive statistics and performed t tests (x2 for
race and tobacco use) for all baseline control variables, comparing
those who progressed to AIDS with those who did not. Kaplan-Meier
estimates and log rank tests were obtained to estimate the survival
probability for psychological and psychosocial variables, which
were grouped by dividing subjects at the median on their average
scores for these variables. Averages were computed using all time
points before the visit when AIDS was diagnosed or using all avail-
able time points for those without AIDS.
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Cox regression models with time-dependent covariates (SAS pro-
cedure PROC PHREG with the EXACT method for handling ties) (43)
were used to calculate the risk of AIDS associated with each psy-
chosocial variable. We used time-dependent covariates at regular
intervals for number of antiretroviral medications, stressful life
events, depression, depressive symptoms, and social support. Be-
cause we hypothesized that these variables might have an additive
effect on disease progression, we used cumulative averages of the
measures. The time-dependent scores at each visit were based on the
average of scores before that visit if progression to AIDS occurred at
that visit; for subjects who had not progressed at that visit, we used
the average of scores up to and including that visit. For example, a
subject’s stress score at visit 3 was the average of scores for visits 1
and 2 if AIDS was diagnosed at visit 3; for those who had not
progressed at this visit, stress scores were the average of visits 1
through 3. All survival analyses were done adjusting for the follow-
ing variables: number of antiretroviral medications, treated as a
time-dependent covariate, and baseline age, years of education, race,
CD41 count, and tobacco use. We first fit the model with only
control variables. Next, we examined the effect of each psychosocial
variable separately, adjusting for control variables. We first exam-
ined psychosocial variables separately because the correlations be-
tween psychosocial variables might obscure some of the findings.
Finally, we fit the model with psychological and psychosocial vari-
ables entered simultaneously with control variables.
For the small number of men who missed visits but continued to
participate in the study, these missing data points were estimated
from the previous 6-months data. We checked the proportionality
assumption of the time-independent variables by testing the statis-
tical significance of the interactions between those variables and
follow-up time; none were significant. We checked the linearity of
the covariate effects by adding in the squared term of each covariate;
the squared term was always nonsignificant. We also checked for
outliers by examining the distributions of depressive symptoms and
stressful life events as well as performing square root transforma-
tions on depressive symptoms; outliers did not account for our
results. Because of our strict initial exclusion criteria, we had so few
men with DSM-III-R alcohol dependence (N 5 6) or drug depen-
dence (N 5 1) that we were unable to evaluate the effects of these
variables.
RESULTS
At entry, the 82 men were an average of 30.3 years
old (SD 5 5.9 years) and had an average of 14.3 years
of education (SD 5 2.4 years). Seventy-nine percent
were white; all but one of the nonwhites were African
American. At the beginning of the study, all men were
clinically asymptomatic (CDC stage A1 or A2) with a
mean CD41 lymphocyte count of 397.4 (SD 5 133.6).
During the study, 33% progressed to AIDS; the av-
erage time to AIDS progression was 2.6 years (SD 5 1.4
years). The average length of time in the study was 3.6
years (SD 5 1.7 years) for those without AIDS. The
number of men studied at 1, 2, 3, 4, 5, and 5.5 years
was 77, 69, 62, 55, 21, and 13, respectively. The last
year had far fewer men because many had not been
scheduled for their 5-year visit. Only eight of the 82
(9.8%) men died of HIV-related causes during this
5.5-year period. The mean stress scores at all visits
ranged from 3.0 to 9.9 (range of individual scores 5
0–23). The mean depressive symptoms scores at all
visits ranged from 1.5 to 2.5 (range of individual
scores 5 0–21). The mean social support scores at all
visits ranged from 4.9 to 5.2. No subjects were taking
protease inhibitors before diagnosis of AIDS or before
study participation ended for those without disease
change.
Table 1 provides descriptive information about the
baseline control variables, comparing men who pro-
gressed to AIDS to those without AIDS. There were no
statistically significant differences between those with
and without AIDS in race, age, education, and tobacco
use. As expected, men who developed AIDS tended to
have lower CD41 lymphocyte counts at baseline than
men who did not progress.
Survival analysis techniques were used to show the
simultaneous effects of control variables on HIV pro-
gression to AIDS (Table 2). Race and baseline CD41
lymphocyte count were significant predictors of AIDS
diagnosis. White men had five times the risk of devel-
oping AIDS compared with nonwhite men. For every
1-cell/ml decrease in CD41 T-helper cell count at base-
line, the risk of developing AIDS increased by about
1%. Likewise, for every 100-cell/ml decrease in CD41
T-helper cell count, a man had slightly more than a
two-fold increased risk of AIDS. Note that age, years of
education, tobacco use, and number of antiretroviral
medications were not significant in predicting disease
progression.
Figures 1, 2, and 3 show the Kaplan-Meier estimates
of the distributions of time until AIDS diagnosis, di-
viding subjects by the medians of stressful life events
(median 5 5.4), depressive symptoms (median 5
1.65), and social support (median 5 5.15). There were
significant differences between the survival distribu-
tions based on grouped data for stress (p 5 .01), de-
pressive symptoms (p 5 .007), and social support (p 5
TABLE 1. Descriptive Data on Control Variables at Entry by
Disease Progression Status
Control Variables
at Entry
AIDS Progression
With AIDS
(N 5 27)
Without AIDS
(N 5 55)
pa
Race (% white) 88.9 74.5 .13
Age (yr)b 30.1 6 5.2 30.3 6 6.3 .87
Education (yr)b 14.3 6 2.3 14.1 6 2.5 .70
CD41 lymphocyte count
(cells/ml)b
337.9 6 97.4 426.7 6 139.9 .001
Tobacco use (% yes) 44.4 41.8 .82
a p values for age, education, and CD41 lymphocyte count were
based on t tests comparing those with AIDS with those without
AIDS; p for race and tobacco use were based on x2 tests.
b Mean 6 SD.
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.008) but not for major depression (p 5 .13). At 66
months, those below the median on stressful life
events had a 28% higher probability of being free of
AIDS compared with those above the median. Like-
wise, those below the median on depressive symptoms
at 66 months had a 39% higher probability of being
free of AIDS compared with those above the median at
that time. Finally, at 66 months, those above the me-
dian on social support had a 40% higher probability of
being free of AIDS compared with those below the
median.
Table 3 shows the separate effects of each psycho-
logical and psychosocial variable (as time-dependent
covariates) on the risk of progressing to AIDS, adjust-
ing for control variables. For each 1-point increase in
cumulative average stressful life events (range of cu-
mulative averages from 0 to 23), the risk of AIDS pro-
gression increased by 21%. For every 4-point increase
in average stressful life events, the equivalent of one
severe stressor or two moderate stressors, the risk of
AIDS was doubled.
For each 1-point increase in cumulative average
depressive symptoms (HDRS-11) (range of cumulative
average 5 0–11.7), there was a 30% increased risk of
AIDS. Likewise, for every 3-point increase in average
depressive symptoms, the equivalent of one severe
symptom, the risk of AIDS progression doubled. Iden-
tical results were found using the original HDRS-17.
Although not significant, there was a trend for major
depression to be associated with faster AIDS progres-
sion. Having at least one major depression (before dis-
ease progression or end of study participation) was
more common among those with AIDS (33.3%) com-
pared with those without AIDS (16.4%) (x2 5 3.04, p 5
.08).
Table 3 also shows that for each point increase in
cumulative average social support satisfaction (range
of cumulative average 5 2.3–6.0), the risk of AIDS
progression decreased by 63%. Stated another way,
with each 1-point decrease in cumulative average so-
cial support satisfaction, the risk of AIDS increased 2.7
times. Number of social support persons was unrelated
to AIDS progression.
In the last step, we tested stress, depressive symp-
toms, and social support in the model together with
control variables (see Table 4). Note that race, baseline
CD41 lymphocyte count, stressful life events, and so-
cial support remained significant in the model. De-
pressive symptoms was reduced to nonsignificance by
the variables of stressful life events and social support.
Depressive symptoms was somewhat correlated with
both stressful life events (median r 5 0.21) and social
support (median r 5 20.21). This shared variance may
have diminished the association of depressive symp-
toms with disease progression. None of the interac-
tions between psychosocial variables were significant
in predicting progression to AIDS.
DISCUSSION
It is widely believed that stress can affect one’s
health. Studies have found that stressful events are
related to decreases in immune status in a variety of
populations (7, 9). Our study is among the first long-
term prospective studies to provide preliminary evi-
dence that the cumulative experience of stressful
events and difficulties and social support may have a
measurable impact on disease progression in HIV-in-
fected men.
Specifically, we showed that for every 4-point in-
crease in cumulative average stressful life events,
equivalent to one severe stressor or two moderate
stressors, the risk of AIDS was doubled. For each
1-point decrease in cumulative average social support,
the risk of AIDS increased almost three-fold. At 5.5
years, the probability of getting AIDS was about two to
three times higher among those above the median on
stress or below the median on social support as com-
pared with those below the median on stress or above
the median on support, respectively.
Although depressive symptoms was also related to
increased risk of AIDS, only stress and social support
remained significant in the model when the three psy-
chological variables were considered together. Depres-
sive symptoms was moderately correlated with the
stress and social support measures, perhaps explain-
ing a similar part of the variance in AIDS progression.
The effects of stress and social support were shown
after controlling for possible confounding factors (eg,
TABLE 2. Cox Regression Model: Hazard of AIDS Diagnosis
With Control Variablesa
b p
Hazard
Ratio
95%
Confidence
Interval
Age 20.02 .51 0.98 0.91–1.05
Education 20.05 .61 0.95 0.78–1.16
Raceb 1.61 .01 5.01 1.37–18.33
Baseline CD41 count (cells/ml) 20.01 .0003 0.99 0.99–1.00
Tobacco usec 0.23 .61 1.26 0.52–3.04
Number of antiretrovirals 20.11 .83 0.90 0.33–2.43
a Results are from a Cox regression model with number of antiretro-
viral medications used (0 to 3) as a time-dependent covariate using
cumulative proportions. Other variables are baseline measures. All
variables were simultaneously entered into the models. b refers to
the unstandardized regression coefficient estimate.
b 0 5 nonwhite; 1 5 white.
c 0 5 no; 1 5 yes.
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age, education, race, baseline helper cells, tobacco use,
and number of antiretroviral medications); none of our
men were taking protease inhibitors before the onset of
AIDS.
Major depression episodes were not significantly
related to AIDS progression; there was a nonsignificant
trend for those with AIDS to be twice as likely to have
had one or more major depressions before AIDS onset
compared with those who did not progress. Few men
were depressed at any time point, which may explain
why the diagnosis of depression was unrelated to
AIDS progression, whereas the depressive symptoms
Fig. 1. Kaplan-Meier estimate of the distribution of time (in months) until AIDS diagnosis by stressful life events.
Fig. 2. Kaplan-Meier estimate of the distribution of time (in months) until AIDS diagnosis by depressive symptoms.
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measure, which allowed for more variance, was re-
lated to AIDS progression in the absence of other psy-
chosocial variables. The lack of variance on major
depression may not allow us to evaluate its effects.
Our present data on men studied for up to 5.5 years
are consistent with those of some recent studies that
followed HIV-infected men over long time periods
(18, 19, 26). Furthermore, the current data extend ear-
lier findings from this cohort that severe stress was
associated with first change in HIV disease stage (21)
and that severe stress and depressive symptoms were
related to declines in several lymphocyte subsets (20).
Previously, we examined the effects of severe
stresses on early disease progression and immune
change; however, this analysis focused on total
stresses (mild, moderate, and severe). Although the
time-dependent measure of severe stress at each visit
was also predictive of AIDS progression (b 5 0.25, p 5
.01, hazard ratio 5 1.29, 95% confidence interval 5
1.06–1.56), we used the total stress score because these
findings tended to be more robust.
Fig. 3. Kaplan-Meier estimate of the distribution of time (in months) until AIDS diagnosis by social support satisfaction.
TABLE 3. Four Cox Regression Models: Hazard of AIDS
Diagnosis With Time-Dependent Psychological and Psychosocial
Variablesa
b p
Hazard
Ratio
95%
Confidence
Interval
Stressful life events 0.19 .002 1.21 1.07–1.36
Major depression diagnosis 1.38 .09 3.96 0.80–19.57
Depressive symptoms (HDRS-11) 0.26 .008 1.30 1.07–1.58
Social support satisfaction 20.99 .0002 .37 0.22–0.63
a Results are from four Cox regression models with each time-depen-
dent predictor variable (using cumulative proportions) run sepa-
rately holding constant the number of antiretroviral medications
used (time-dependent covariate) and baseline age, education, race,
CD41 count, and tobacco use. b refers to the unstandardized regres-
sion coefficient estimate.
TABLE 4. Cox Regression Model: Hazard of AIDS Diagnosis
With Control Variables and Time-Dependent Psychological and
Psychosocial Variablesa
b p
Hazard
Ratio
95%
Confidence
Interval
Age 0.03 .45 1.03 0.95–1.11
Education 20.09 .41 0.92 0.75–1.12
Raceb 1.51 .03 4.52 1.12–18.30
Baseline CD41 count
(cells/ml)
20.01 .0005 0.99 0.98–1.00
Tobacco usec 0.89 .07 2.45 0.92–6.53
Number of antiretrovirals 0.25 .65 1.28 0.44–3.68
Stressful life events 0.15 .03 1.16 1.01–1.33
Depressive symptoms
(HDRS-11)
0.06 .61 1.07 0.84–1.36
Social support satisfaction 20.82 .006 0.44 0.24–.79
a Results are from one Cox regression model with all variables en-
tered into the equation simultaneously. Number of antiretroviral
medications used, stressful life events, depressive symptoms, and
support satisfaction are time-dependent covariates using cumulative
proportions; the other variables are baseline values. b refers to the
unstandardized regression coefficient estimate.
b 0 5 nonwhite; 1 5 white.
c 0 5 no; 1 5 yes.
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We must be cautious in interpreting the data from
our study. First, we do not know whether our findings
can be generalized beyond our sample, a group of gay
men from both rural and urban areas of North Carolina.
We may not be able to generalize our results to such
groups as women, intravenous drug users, and those in
other geographic areas. Second, we could not control
for length of time with HIV infection because date of
infection was unknown; however, our findings re-
mained after controlling for baseline helper count, an
approximation of disease stage. Consistent with other
investigators (14, 15, 19, 44), we found that men with
low helper counts at baseline had faster disease pro-
gression. It would also be useful to replicate our find-
ings in studies using viral load as the indicator of
disease progression.
A third caution for data interpretation is the prob-
lem of establishing the causal direction of relation-
ships between psychological variables and disease
progression. Do depressive symptoms contribute to
disease progression, or are these psychological
changes an early manifestation of the disease process?
This latter hypothesis was suggested by Lyketsos et al.
(22) to explain their finding that depressive symptoms
seem to increase before clinical AIDS is diagnosed.
Other researchers consider psychological factors like
depression to be risk factors for the development of
HIV-related symptoms, especially when the psycho-
logical variables are shown to occur before clinical
progression (18, 19). We attempted to address this
causal issue in several ways. First, we used time-
dependent psychological variables during the time
points before AIDS diagnosis. Second, we excluded
somatic symptoms associated with HIV disease pro-
gression (eg, weight loss and gastrointestinal symp-
toms) from the measure of depressive symptoms. More
importantly, we used measures of stressful life events
and social support, which may be less likely to reflect
early manifestations of HIV disease progression. The
measure of stressful life events excluded stressors that
might be caused by disease progression, such as losing
one’s job because of a change in HIV status. Stressful
events were also scored independently from the sub-
ject’s perception of the stress and way of coping. This
objective stress rating helped reduce the possibility
that worsening disease may have led to poorer coping
and higher stress scores. Thus, this measure of stress-
ful life events may be the best evidence of an effect of
psychosocial variables because it is the least likely to
be confounded with disease progression.
The fact that a variety of psychosocial measures are
related to disease progression seems to support our
findings and may indicate that some underlying factor
related to these variables may be predictive of disease
progression. Although we controlled for smoking and
number of antiretroviral medications used, perhaps
other health behaviors (eg, amount of sleep, diet, ex-
ercise, and compliance with medication use) and neu-
roendocrine and immune variables might mediate the
relationship of stress and social support with disease
progression. Our earlier studies showing reductions in
CD81 and natural killer lymphocyte subsets among
men with scores above the median on both stress and
depressive symptoms (16, 20) might support a medi-
ating role of these lymphocyte subsets.
Although we found that African American subjects
had slower HIV disease progression than white sub-
jects, other studies have not shown such an effect of
race(19, 44–46). The race effect in the current study
may be limited to our sample and needs further study.
In conclusion, the finding regarding the cumulative
effects of stressful life events, a psychosocial measure
less likely to be confounded with disease progression,
is perhaps among the most compelling evidence to
date linking psychosocial variables with HIV disease
progression. Men averaging two moderate stressors
had a two-fold increased risk of AIDS progression
compared with men with no stressors. It will be im-
portant to determine whether other long-term longitu-
dinal studies can replicate our findings in HIV-
positive women and to determine whether stress, de-
pressive symptoms, and social support are risk factors
for mortality in HIV infection. Additional study will be
necessary to elucidate the mechanisms that underlie
these relationships. In addition, we will need to deter-
mine whether cognitive behavioral interventions that
have been shown to reduce distress and improve social
support (47–49) can alter the course of HIV infection.
Shedding light on the nature of the relationships be-
tween HIV disease progression and psychological vari-
ables may help with the treatment of those infected
with HIV.
This study was supported in part by National Insti-
tute of Mental Health Grants MH-44618 and MH-33127
and by National Institutes of Health Grant RR-00046.
REFERENCES
1. Frasure-Smith N, Lesperance F, Talajic M. Depression following
myocardial infarction: impact on 6-month survival. JAMA 1993;
270:1819–25.
2. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-
month prognosis after myocardial infarction. Circulation 1995;
91:999–1005.
3. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL,
Morton DL. Malignant melanoma: effects of an early structured
psychiatric intervention, coping, and affective state on recur-
rence and survival 6 years later. Arch Gen Psychiatry 1993;50:
681–9.
J. LESERMAN et al.
404 Psychosomatic Medicine 61:397–406 (1999)
4. Spiegel D, Kraemer HC, Bloom JR, Gottheil E. Effect of psycho-
social treatment on survival of patients with metastatic breast
cancer. Lancet 1989;2:888–91.
5. Ramirez AJ, Craig TJK, Watson JP, Fentiman IS, North WRS,
Rubens RD. Stress and relapse of breast cancer. BMJ 1989;298:
291–3.
6. Rovner BW, German PS, Brant LJ, Clark R, Burton L, Folstein
MF. Depression and mortality in nursing homes. JAMA 1991;
265:993–6.
7. Evans DL, Leserman J, Golden RN, Lewis MH, Folds JA, Ozer H.
Immune correlates of stress and depression. Psychopharmacol
Bull 1989;25:319–24.
8. Evans DL, Folds JD, Petitto JM, Golden RN, Pedersen CA, Cor-
rigan M, Gilmore JH, Silva SG, Quade D, Ozer H. Circulating
natural killer cell phenotypes in males and females with major
depression: relation to cytotoxic activity and severity of depres-
sion. Arch Gen Psychiatry 1992;49:388–95.
9. Herbert TB, Cohen S. Stress and immunity in humans: a meta-
analytic review. Psychosom Med 1993;55:364–79.
10. Herbert TB, Cohen S. Depression and immunity: a meta-analytic
review. Psychol Bull 1993;113:3:472–86.
11. Reichlin S. Mechanisms of disease: neuroendocrine-immune
interactions. N Engl J Med 1993;329:1246–53.
12. Stein M, Miller AH, Trestman RL. Depression, the immune
system and health and illness. Arch Gen Psychiatry 1991;48:
171–7.
13. Fauci AS. Multifactorial nature of human immunodeficiency
virus disease: implications for therapy. Science 1993;262:
1011–8.
14. Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML,
Coates TJ. Depressive symptoms and CD4 lymphocyte decline
among HIV-infected men. JAMA 1993;270:2568–73.
15. Lyketsos CG, Hoover DR, Guccione M, Senterfitt W, Dew MA,
Wesch J, VanRaden MJ, Treisman GJ, Morgenstern H. Depressive
symptoms as predictors of medical outcomes in HIV infection.
JAMA 1993;270:2563–7.
16. Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Tamul
K, Liao D, van der Horst CM, Hall CD, Folds JD, Golden RN,
Petitto JM. Stress-associated reductions of cytotoxic T lympho-
cytes and natural killer cells in asymptomatic HIV infection.
Am J Psychiatry 1995;152:543–50.
17. Zorrilla EP, McKay JR, Luborsky L, Schmidt K. Relation of
stressors and depressive symptoms to clinical progression of
viral illness. Am J Psychiatry 1996;153:626–35.
18. Mayne TJ, Vittinghoff E, Chesney MA, Barrett DC, Coates TJ.
Depressive affect and survival among gay and bisexual men
infected with HIV. Arch Intern Med 1996;156:2233–8.
19. Page-Shafer K, Delorenze GN, Satariano W, Winkelstein W Jr.
Comorbidity and survival in HIV-infected men in the San Fran-
cisco Men’s Health Survey. Ann Epidemiol 1996;6:420–30.
20. Leserman J, Petitto JM, Perkins DO, Folds JD, Golden RN, Evans
DL. Severe stress, depressive symptoms, and changes in lym-
phocyte subsets in human immunodeficiency virus-infected
men. Arch Gen Psychiatry 1997;54:279–85.
21. Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Zheng
B, Gettes D, Longmate JA, Silva SG, van der Horst CM, Hall CD,
Folds JD, Golden RN, Petitto JM. Severe life stress as a predictor
of early disease progression in HIV infection. Am J Psychiatry
1997;154:630–4.
22. Lyketsos CG, Hoover DR, Guccione M, Dew MA, Wesch JE, Bing
EG, Treisman GJ. Changes in depressive symptoms as AIDS
develops. Am J Psychiatry 1996;153:1430–7.
23. Lyketsos CG, Hoover DR, Guccione M. Depression and survival
among HIV-infected persons. JAMA 1996;275:35–6.
24. Patterson TL, Semple SJ, Temoshok LR, Atkinson JH, Mc-
Cutchan JA, Straits-Troster K, Chandler JL, Grant I. Stress and
depressive symptoms prospectively predict immune change
among HIV-seropositive men. Psychiatry 1995;58:299–312.
25. Ironson G, Friedman A, Klimas N, Antoni M, Fletcher MA,
LaPerriere A, Simoneau J, Schneiderman N. Distress, denial,
and low adherence to behavioral interventions predict faster
disease progression in gay men infected with human immuno-
deficiency virus. Int J Behav Med 1994;1:90–105.
26. Kemeny ME, Dean L. Effects of AIDS-related bereavement on
HIV progression among New York City gay men. AIDS Educ
Prev 1995;7:36–47.
27. Perry S, Fishman B, Jacobsberg L, Frances A. Relationships over
one-year between lymphocyte subsets and psychosocial vari-
ables among adults with infection by human immunodeficiency
virus. Arch Gen Psychiatry 1992;49:396–401.
28. Rabkin JG, Williams JBW, Remien RH, Goetz RR, Dertzner R,
Gorman JM. Depression, distress, lymphocyte subsets, and hu-
man immunodeficiency virus symptoms on two occasions in
HIV-positive homosexual men. Arch Gen Psychiatry 1991;48:
111–9.
29. Kessler RC, Foster C, Joseph J, Ostrow D, Wortman C, Phair J,
Chmiel J. Stressful life events and symptom onset in HIV infec-
tion. Am J Psychiatry 1991;148:733–8.
30. Theorell T, Blomkvist V, Jonsson H, Schulman S, Berntorp E,
Stigendal L. Social support and the development of immune
function in human immunodeficiency virus infection. Psycho-
som Med 1995;57:32–5.
31. Solano L, Costa M, Salvati S, Coda R, Aiuti F, Mezzaroma I,
Bertini M. Psychological factors and clinical evolution in HIV-1
infection: a longitudinal study. J Psychosom Res 1993;37:39–51.
32. Centers for Disease Control and Prevention. Revision of the CDC
surveillance case definition for acquired immunodeficiency
syndrome. Morb Mortal Wkly Rep (MMWR) 1987;36(suppl 1):
1S–5S.
33. Petitto JM, Folds JD, Ozer H, Quade D, Evans DL. Altered diur-
nal variation in natural killer cell phenotypes and cytotoxic
activity in major depression. Am J Psychiatry 1992;149:5:694–6.
34. Perkins DO, Dickison JA, Evans DL. SCID-RDC: DSM-III-R and
RDC integrated interview [abstract]. Proceedings of the Ameri-
can Psychiatric Association. American Psychiatric Association,
New York. May 1990; p. 75.
35. Perkins DO, Stern RA, Golden RN, Murphy C, Naftolowitz D,
Evans DL. Mood disorders in HIV infection: prevalance and risk
factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry
1994;151:233–6.
36. Hamilton M. A rating scale for depression. J Neurol Neurosurg
Psychiatry 1960;23:56–62.
37. Dohrenwend BS, Krasnoff L, Askenasy AR, Dohrenwend BP.
Exemplification of a method for scaling life events: The PERI
Life Events Scale. J Health Soc Behav 1978;19:205–29.
38. Brown GW, Harris T. Social origins of depression: a study of
psychiatric disorder in women. New York: Free Press; 1978.
39. Grant I, Brown GW, Harris T, McDonald WI, Patterson TL.
Severely threatening events and marked life difficulties preced-
ing onset or exacerbation of multiple sclerosis. J Neurol Neuro-
surg Psychiatry 1989;52:8–13.
40. Sarason IG, Sarason BR, Shearin EN, Pierce GR. A brief measure
of social support: practical and theoretical implications. J Soc
Pers Relat 1987;4:497–510.
41. Leserman J, DiSantostefano R, Perkins DO, Murphy C, Golden
RN, Evans DL. Longitudinal study of social support and social
conflict as predictors of depression and dysphoria among HIV-
positive and HIV-negative men. Depression 1994;2:189–99.
STRESS, SOCIAL SUPPORT, AND PROGRESSION TO AIDS
405Psychosomatic Medicine 61:397–406 (1999)
42. Centers for Disease Control and Prevention. Revised classifica-
tion system for HIV infection and expanded surveillance case
definition for AIDS among adolescents and adults. Morb Mortal
Wkly Rep (MMWR) 1992;1993:41:1–15.
43. Allison PD. Survival analysis using the SAS system: a practical
guide. Cary, NC: SAS Institute Inc., 1995. p. 61–184.
44. Poole WK, Fulkerson W, Lou Y, Kvale P, Hopewell PC, Hirschtick
R, Glassroth J, Rosen M, Mangura B, Wallace J, Markowitz N.
Overall and cause-specific mortality in a cohort of homo-/bisexual
men, injecting drug users, and female partners of HIV-infected
men: pulmonary complications of Human Immunodeficiency Vi-
rus Infection Study group. AIDS 1996;10:1257–64.
45. Garland FC, Garland CF, Gorham ED, Brodine SK. Western blot
banding patterns of HIV rapid progressors in the US Navy sero-
positive cohort: implications for vaccine development. Navy
Retroviral Working Group. Ann Epidemiol 1996;6:341–7.
46. Corn BW, Donahue BR, Rosenstock JG, Hyslop T, Brandon A,
Hegde HH, Cooper JS, Sherr DL, Fisher SA, Berson A, Han H,
Abdel-Wahab M, Koprowski CD, Ruffer JE, Curran WJ Jr. Perfor-
mance status and age as independent predictors of survival
among AIDS patients with primary CNS lymphoma: a multivar-
iate analysis of a multi-institutional experience. Cancer J Sci Am
1997;3:52–6.
47. Lutgendorf SK, Antoni M, Ironson G, Starr K, Costello N, Zuck-
erman M, Klimas N, Fletcher MA, Schneiderman N. Changes in
cognitive coping skills and social support during cognitive be-
havioral stress management intervention and distress outcomes
in symptomatic human immunodeficiency virus (HIV)-
seropositive gay men. Psychosom Med 1998;60:204–14.
48. Chesney MA, Folkman S, Chambers D. Coping effectiveness
training for men living with HIV: preliminary findings. Int J STD
AIDS 1996;7:75–82.
49. Mulder CL, Emmelkamp PM, Antoni M, Mulder JW, Sandfort
TG, de Vries MJ. Cognitive-behavioral and experiential group
psychotherapy for HIV-infected homosexual men: a compara-
tive study. Psychosom Med 1994;56:423–31.
J. LESERMAN et al.
406 Psychosomatic Medicine 61:397–406 (1999)
